News | Stroke | October 31, 2018

Medication Alone May Not Eliminate Stroke Risk in Carotid Atherosclerotic Stenosis Patients

New study assesses risk factor profile and anatomic features of previously asymptomatic patients presenting with carotid-related stroke

Medication Alone May Not Eliminate Stroke Risk in Carotid Atherosclerotic Stenosis Patients

October 31, 2018 — Recent statin and medication advances have led some researchers to suggest surgical treatments for carotid stenosis should be limited to symptomatic patients ­–  primarily those who have already had a stroke or transient ischemic attack (TIA). However, a new study published in the Journal of Vascular Surgery questions whether medical therapy is a sufficient stroke-reduction strategy.1

In the study, only 35 percent of stroke patients were receiving both statin and antiplatelet agents prior to their event, suggesting that asymptomatic carotid disease is unrecognized in many individuals, noted lead researcher W. Darrin Clouse, M.D., of Massachusetts General Hospital (MGH).

“And the first manifestation of their disease,” he wrote, “could be the occurrence of a stroke.”

Stroke is the second most common cause of death and third most common cause of disability worldwide.  Carotid revascularization, either by endarterectomy or stent, has a proven track record in preventing stroke in both asymptomatic and symptomatic patients with significant carotid disease.

Direct comparison between modern antiplatelet/statin regimens and carotid revascularization is ongoing in the CREST-2 Trial, but these results are years away from confirmation.

As reported in the November edition of the Journal of Vascular Surgery, researchers from MGH led by Clouse and first author Derek Klarin, M.D., assessed the atherosclerotic risk factor profiles, anatomic features and clinical outcomes of previously asymptomatic patients admitted after a carotid-related stroke. Records from 3,381 patients admitted with an ischemic stroke between 2005 and 2015 were reviewed, revealing 219 patients (7 percent) were due to carotid disease.

Demographics of those with strokes secondary to carotid disease included:

  • Sixty-one percent white;
  • Sixty-six percent male;
  • Mean age 68 +/- 12 years;
  • Hypertensive 79 percent; and
  • Tobacco abuse, 33 percent current, 29 percent former.

Medical therapy noted upon admission involved:

  • Fifty percent antiplatelet therapy;
  • Fifty-five percent lipid lowering agents; and
  • Thirty-five percent receiving both.

Carotid disease in these stroke patients was noted to be:

  • Forty-three percent with total occlusion;
  • Forty-seven percent with high-grade stenosis (>70 percent); and
  • Ten percent with moderate stenosis (>50-70 percent).

Seventy-one percent of patients were determined to have had a moderate-severe stroke.  Those receiving both antiplatelet and statin therapy were less likely to have this degree of stroke (44 percent versus 78 percent).

“Nearly one-half of the patients we identified presented with complete internal carotid occlusion at time of their first symptoms, largely making them ineligible for stroke-risk reduction with CEA or stenting,” noted Clouse.  “The effect of this inability to salvage carotid perfusion in patients with occlusion should be included in the assessment of risks and benefits associated with asymptomatic carotid revascularization.”

Clouse added, “Taken together, these data suggest that medical therapy alone is unlikely to completely extinguish stroke risk in patients with significant carotid bifurcation atherosclerotic stenosis. The proper identification of stenosis, medical therapy institution, proper surveillance for progression and revascularization are all important in minimizing progression to carotid-related stroke.”

The authors also note that of the stroke patients, only 7 percent had been screened, but 35 percent had been receiving both statin and antiplatelet agents, suggesting that some atherosclerotic disease had been detected.

While advances have been made in the medical treatment of carotid atherosclerosis, this analysis of stroke patients argues strongly for the continued role of revascularization pending the results of the CREST-2 Trial.

For more information: www.vsweb.org

 

Reference

1. Klarin D., Cambria R.P., Ergul E.A., et al. Risk factor profile and anatomic features of previously asymptomatic patients presenting with carotid-related stroke. Journal of Vascular Surgery, published online May 24, 2018. https://doi.org/10.1016/j.jvs.2018.01.064

 

Related Content

Advances in Anticoagulants Expand Options for VTE Prevention, Treatment
News | Antiplatelet and Anticoagulation Therapies | July 26, 2019
A new article published in AACN Advanced Critical Care outlines the traditional anticoagulant therapies familiar to...
Fragmin (dalteparin sodium) injection was cleared by the FDA for use in pediatric patients. It was initially approved by the FDA in 1994 for adults and is a type of heparin.

Fragmin (dalteparin sodium) injection is now cleared by the FDA for use in pediatric patients. It was initially approved by the FDA in 1994 for adults and is a type of heparin.

Technology | Antiplatelet and Anticoagulation Therapies | May 17, 2019
May 17, 2019 — The U.S.
PhaseBio Receives FDA Breakthrough Therapy Designation for Ticagrelor Reversal Agent
Technology | Antiplatelet and Anticoagulation Therapies | April 30, 2019
PhaseBio Pharmaceuticals Inc. announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy...
People With Heart Disease at Risk When Pharmacies Close
News | Antiplatelet and Anticoagulation Therapies | April 24, 2019
April 24, 2019 — New research from the University of Illinois at Chicago shows that when pharmacies close, people sto
Study Finds Only Six Percent of Patients Taking Statins as Directed
News | Antiplatelet and Anticoagulation Therapies | April 18, 2019
A recent study found patients with atherosclerotic cardiovascular disease cut their risk of a second major adverse...
HonorHealth Research Institute Launches SynIVUS-DAPT Study
News | Antiplatelet and Anticoagulation Therapies | April 16, 2019
HonorHealth Research Institute announced the first patients have been enrolled in the SynIVUS-DAPT Study. The clinical...
Lack of Physician Guidance, Fear of Side Effects Influence Statin Compliance
News | Antiplatelet and Anticoagulation Therapies | April 15, 2019
Despite national guidelines indicating statins can lower risk of heart attack and stroke, many patients who could...
Stopping DAPT After One Month Improved Outcomes in Stent Patients
News | Antiplatelet and Anticoagulation Therapies | March 25, 2019
Patients who stopped taking aspirin one month after receiving a stent in the heart’s arteries but continued taking the...
Apixaban Effective in Specific Cohort of Non-Valvular Atrial Fibrillation Patients
News | Antiplatelet and Anticoagulation Therapies | March 19, 2019
The Bristol-Myers Squibb-Pfizer Alliance announced results from the Phase 4 AUGUSTUS trial evaluating Eliquis (apixaban...
Researchers Develop Reversible, Drug-Free Antiplatelet Therapy
News | Antiplatelet and Anticoagulation Therapies | February 19, 2019
A new reversible, drug-free antiplatelet therapy could reduce the risk of blood clots and potentially prevent cancer...
Overlay Init